Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126874551 | 12687455 | 1 | I | 20160620 | 20160825 | 20160825 | PER | US-ASTRAZENECA-2016SE68305 | ASTRAZENECA | 0.00 | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126874551 | 12687455 | 1 | PS | BRILINTA | TICAGRELOR | 1 | Oral | 22433 | 90 | MG | TABLET | Q12H | |||||||
| 126874551 | 12687455 | 2 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 22433 | 90 | MG | TABLET | Q12H | |||||||
| 126874551 | 12687455 | 3 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | 25.0MG AS REQUIRED | U | U | 0 | 25 | MG | TABLET | |||||
| 126874551 | 12687455 | 4 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | 25.0MG AS REQUIRED | U | U | 0 | 25 | MG | TABLET | |||||
| 126874551 | 12687455 | 5 | C | PANTAPROZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 6 | C | OXYBUTYNIN | OXYBUTYNIN | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 7 | C | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 8 | C | DIGOXIN. | DIGOXIN | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 9 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 10 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 11 | C | TIZANITINE HCL | 2 | 0 | |||||||||||||
| 126874551 | 12687455 | 12 | C | CHLORDIAZETOXIDE | 2 | 0 | |||||||||||||
| 126874551 | 12687455 | 13 | C | LOSARTAN. | LOSARTAN | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 14 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 15 | C | XANAX | ALPRAZOLAM | 1 | 0 | ||||||||||||
| 126874551 | 12687455 | 16 | C | ACETAMINOPHEN COD | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126874551 | 12687455 | 1 | Acute coronary syndrome |
| 126874551 | 12687455 | 2 | Stent placement |
| 126874551 | 12687455 | 3 | Blood pressure measurement |
| 126874551 | 12687455 | 4 | Heart rate increased |
| 126874551 | 12687455 | 5 | Gastrooesophageal reflux disease |
| 126874551 | 12687455 | 6 | Bladder discomfort |
| 126874551 | 12687455 | 8 | Heart rate irregular |
| 126874551 | 12687455 | 9 | Blood cholesterol |
| 126874551 | 12687455 | 11 | Muscle spasms |
| 126874551 | 12687455 | 12 | Anxiety |
| 126874551 | 12687455 | 13 | Blood pressure measurement |
| 126874551 | 12687455 | 14 | Acute coronary syndrome |
| 126874551 | 12687455 | 15 | Anxiety |
| 126874551 | 12687455 | 16 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126874551 | 12687455 | Contusion | |
| 126874551 | 12687455 | Drug hypersensitivity | |
| 126874551 | 12687455 | Dyspnoea | |
| 126874551 | 12687455 | Musculoskeletal discomfort | |
| 126874551 | 12687455 | Osteoporosis | |
| 126874551 | 12687455 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126874551 | 12687455 | 1 | 201509 | 0 | ||
| 126874551 | 12687455 | 2 | 201509 | 0 |